权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Mechanistic analysis and allellic genome editing of iPSC-derived dominant LCA model

iPSC 衍生的显性 LCA 模型的机制分析和等位基因组编辑

基本信息

批准号：
10514970
负责人：
Deepak Ashok Lamba
金额：
$ 11.49万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-01-01 至 2025-11-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10514970
关键词：
Affect Alleles Binding Binding Sites Biochemical Biological Models Blindness CRISPR therapeutics CRISPR/Cas technology CRX protein Cell Line Cell Maturation Cell physiology Child Clinic Clustered Regularly Interspaced Short Palindromic Repeats Cone DNA Binding Defect Development Disease Disease model Dominant-Negative Mutation Endonuclease I Excision Foundations Functional disorder Future Genes Genetic Transcription Goals Histologic Human In Vitro Individual Inherited Investigation Knock-out Laboratories Lead Leber&apos s amaurosis Mediating Modeling Mus Mutation Newborn Infant Organoids Pathogenesis Patients Phenotype Photoreceptors Play Protein Analysis Protocols documentation RNA analysis Reporting Retina Retinal Degeneration Retinal Diseases Retinal Dystrophy School-Age Population Solid Testing Therapeutic Variant Vision research Work base developmental disease disease phenotype disease-in-a-dish early onset effective therapy functional restoration gene replacement gene therapy genome editing human subject improved in vitro Model in vivo induced pluripotent stem cell insight loss of function mutation mouse model mutant novel strategies novel therapeutic intervention protein expression protein function protein protein interaction sight restoration stem cell derived tissues stem cells therapeutic gene tool transcription factor

项目摘要

PROJECT SUMMARY Leber congenital amaurosis (LCA) is a group of devastating early-onset retinal dystrophies affecting roughly 1/50,000 to 1/33,000 newborns. LCA-associated variants in the CRX gene result in a severe autosomal dominant form of the disease, for which no effective treatments are currently available. Importantly, both mouse and human studies suggest that haploinsufficiency is not responsible for disease manifestation in dominant CRX- associated LCA, and one copy of wildtype CRX is enough to allow for mostly normal photoreceptor maturation and function. Despite substantial progress being made in the field, there is a critical need to uncover pathophysiology and establish reliable treatment options for CRX-associated LCA. The overall goal of this proposal is to bring together two major unsolved problems in vision research: (1) the ability to accurately recapitulate dominant LCA in a scalable in vitro model system to study variant-specific disease mechanisms, and (2) the ability to efficiently and specifically eliminate dominant disease alleles, leaving healthy alleles to restore photoreceptor cell function. In Aim 1, we will develop and characterize iPSC-based disease models from two different dominant variants of CRX. We will validate disease phenotypes using retinal organoids. In Aim 2, variant-specific disease mechanisms responsible for the onset of LCA will be examined by generating a retinal organoid model system from patient-derived induced pluripotent stem cells. In Aim 3, mutant CRX alleles will be inactivated with CRISPR tools within the human retinal organoid model to study rescue of disease phenotypes. Completion of this aim will provide the field with a proof-of-concept study for the development of patient-specific CRISPR-based therapeutic strategies. Taken together, the proposed studies will contribute to our basic understanding of the pathophysiological mechanisms underlying photoreceptor dysfunction in dominant CRX-associated LCA, and will enable the development of targeted gene therapies to treat affected individuals.

项目总结